checkAd
    Milestone Pharmaceuticals Aktie
    1,5000
     
    USD
    -1,96 %
    -0,0300 USD
    Letzter Kurs 02:00:00 Nasdaq
    1,4900
     
    USD
    3.700 STK
    Geldkurs 31.05.24
    1,5000
     
    USD
    37.400 STK
    Briefkurs 31.05.24
    ISIN: CA59935V1076 · WKN: A2PHG6 · SYM: MIST · Kanada

    Neueste Nachrichten

    Milestone Pharmaceuticals to Participate in the Upcoming Jefferies Global Healthcare Conference
    31.05.24 · globenewswire · Milestone Pharmaceuticals
    Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST
    29.05.24 · globenewswire · Milestone Pharmaceuticals
    Milestone Pharmaceuticals Partners with Arrhythmia Alliance on SVT Awareness
    22.05.24 · globenewswire · Milestone Pharmaceuticals
    Milestone Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Regulatory and Corporate Update
    13.05.24 · globenewswire · Milestone Pharmaceuticals
    Milestone Pharmaceuticals Announces Data Presentations on Etripamil at Heart Rhythm 2024, 2024 Stanford BioDesign Arrhythmia Technologies Retreat, and ISPOR 2024
    02.05.24 · globenewswire · Milestone Pharmaceuticals
    Milestone Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium
    17.04.24 · globenewswire · Milestone Pharmaceuticals
    Milestone Pharmaceuticals Announces Etripamil Data Demonstrating Patients’ Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting
    08.04.24 · globenewswire · Milestone Pharmaceuticals
    Milestone Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference
    03.04.24 · globenewswire · Milestone Pharmaceuticals
    Milestone Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences
    01.04.24 · globenewswire · Milestone Pharmaceuticals
    Milestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia
    28.03.24 · globenewswire · Milestone Pharmaceuticals
    Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update
    21.03.24 · globenewswire · Milestone Pharmaceuticals
    Milestone Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference
    29.02.24 · globenewswire · Milestone Pharmaceuticals